Background Periprosthetic osteolysis resulting in aseptic loosening is a leading cause of THA revision. Individuals vary in their susceptibility to osteolysis and heritable factors may contribute to this variation. However, the overall contribution that such variation makes to osteolysis risk is unknown. Questions/purposes We conducted two genome-wide association studies to (1) identify genetic risk loci associated with susceptibility to osteolysis; and (2) identify genetic risk loci associated with time to prosthesis revision for osteolysis. Methods The Norway cohort comprised 2624 patients after THA recruited from the Norwegian Arthroplasty Registry, of whom 779 had undergone revision surgery for osteolysis. The UK cohort included 890 patients previously
recruited from hospitals in the north of England, 317 who either had radiographic evidence of and/or had undergone revision surgery for osteolysis. All participants had received a fully cemented or hybrid THA using a smalldiameter metal or ceramic-on-conventional polyethylene bearing. Osteolysis susceptibility case-control analyses and quantitative trait analyses for time to prosthesis revision (a proxy measure of the speed of osteolysis onset) in those patients with osteolysis were undertaken in each cohort separately after genome-wide genotyping. Finally, a meta-analysis of the two independent cohort association analysis results was undertaken. Results Genome-wide association analysis identified four independent suggestive genetic signals for osteolysis casecontrol status in the Norwegian cohort and 11 in the UK cohort (p # 5 x 10 -6 ). After meta-analysis, five independent genetic signals showed a suggestive association with osteolysis case-control status at p # 5 x 10 -6 with the strongest comprising 18 correlated variants on chromosome 7 (lead signal rs850092, p = 1.13 x 10 -6 ). Genome-wide quantitative trait analysis in cases only showed a total of five and nine independent genetic signals for time to revision at p # 5 x 10 -6 , respectively. After meta-analysis, 11 independent genetic signals showed suggestive evidence of an association with time to revision at p # 5 x 10 -6 with the largest association block comprising 174 correlated variants in chromosome 15 (lead signal rs10507055, p = 1.40 x 10 -7
). Conclusions We explored the heritable biology of osteolysis at the whole genome level and identify several genetic loci that associate with susceptibility to osteolysis or with premature revision surgery. However, further studies are required to determine a causal association between the identified signals and osteolysis and their functional role in the disease. Clinical Relevance The identification of novel genetic risk loci for osteolysis enables new investigative avenues for clinical biomarker discovery and therapeutic intervention in this disease.
Introduction
Despite improvements in modern prosthetic design, 5% to 10% of THA prostheses undergo revision within 10 years [28, 32] . Although osteolysis after THA has been mitigated by the use of highly crosslinked polyethylene bearings [22] , osteolysis and its sequelae aseptic loosening remain a leading indication for revision surgery, accounting for 55% of THA revision procedures worldwide [43] . Revision surgery carries a three-to eightfold greater inhospital mortality, higher morbidity, and poorer functional outcome versus primary THA [9, 31, 58] .
Aseptic loosening is the clinical endpoint of periprosthetic osteolysis, which describes a progressive resorption of bone caused by a host inflammatory response to particulate wear debris [15, 25, 44, 45] . This inflammatory bone loss is mediated by proinflammatory cytokines that upregulate osteoclastogenesis directly or indirectly through receptor activator of nuclear factor kB ligand signaling [7, 19-21, 24, 52, 56] while also downregulating osteoblastogenesis [27] . The exact mechanisms involved in this process are still not fully understood, although several studies have implicated innate immune signaling through pattern recognition receptor activation by danger and pathogen-associated molecular patterns [3, 5, 41, 48] .
Evidence from in vitro studies suggest that individuals vary in their immunologic response to wear debris [12, 37] ; however, the component of osteolysis that is attributable to heritable factors remains unclear. Similarly, the genes that modulate the time after surgery when osteolysis occurs in patients who develop the disease also remain relatively unexplored and may differ from those that modulate susceptibility. Several investigators have explored the relationship between genetic variation within candidate genes and susceptibility to periprosthetic osteolysis with the first identified association being with the promoter region of the gene encoding tumor necrosis factor (TNF) [53] . Subsequently, several associations between single nucleotide polymorphism (SNPs) in proinflammatory cytokines and bone turnover pathways and osteolysis have been identified [1, 2, 11, 13, 14, 26, 30, 33-35, 47, 51] . However, our knowledge of the genetics of osteolysis is currently based entirely on studies using the "candidate" gene approach in which the threshold for identifying an association is low. The only genetic association with osteolysis identified to date that has been independently replicated is found at the TNF promoter [11, 53] .
Candidate gene studies, which are based on a priori hypotheses about the role of a selected gene or a group of pathway-related genes, have several limitations. These include low sample sizes leading to low statistical power to detect modest to small effect sizes that are characteristic of most complex diseases and incomplete coverage of variation across the genes of interest. Limited knowledge of the etiopathogenesis of disease also restricts the selection of candidate genes and misses variation in genes lying in previously unsuspected pathways. In contrast, genomewide association studies utilize a hypothesis-free approach enabling the examination of a set of maximally informative markers capturing variation across the whole genome. This approach has established thousands of reproducible associations with complex diseases (https://www.ebi.ac.uk/ gwas/) [23, 40] . To date, there have been no systematic studies of the genetic architecture of osteolysis at the whole genome level.
We conducted two genome-wide association studies and a subsequent meta-analysis to (1) identify genetic risk loci associated with susceptibility to osteolysis; and (2) identify genetic risk loci associated with time to prosthesis revision for osteolysis.
Patients and Methods
The Norwegian cohort comprised patients with osteolysis and osteolysis-free matched control patients after THA. The participants were identified from the Norwegian Arthroplasty Register and recruited by postal return of a saliva sample for DNA extraction between April 2009 and December 2011. All patients had previously undergone primary cemented or hybrid (cemented femur) THA for idiopathic osteoarthritis. The recruitment strategy for the Norwegian cohort was planned to minimize confounders between the patients with osteolysis and those in the control group as follows: All live patients recorded in the Norwegian Arthroplasty Register as having had a revision for the indication of osteolysis or aseptic loosening (n = 2029) were invited to participate. The revision patients were recruited first and the control group patients individually matched at a ratio of approximately three to one to be of the same age (6 2 years), sex, implant fixation method, bearing couple material and head size (22-mm or 28-mm bearing only), and year of primary surgery (6 2 years). Patients who had undergone primary THA for an inflammatory arthropathy, femoral neck fracture, secondary osteoarthritis, or who had a history of infection were excluded. Patients who had previously undergone revision arthroplasty were also excluded as were those of selfreported non-European Caucasian ancestry. This exclusion criteria were also confirmed at genotype screening. In all, 923 patients who had previously undergone revision surgery for osteolysis responded to the invitation and provided a saliva sample for DNA analysis. A matched group of 1957 patients identified within the Norwegian Arthroplasty Register as having primary THA for idiopathic osteoarthritis and with no recorded revision surgery episodes for the operated hip provided a saliva sample as diseasenegative controls.
The 890 patients in the UK cohort had been previously recruited into a research program examining the genetics of osteolysis, having previously undergone either cemented or hybrid THA with a metal-on-conventional polyethylene bearing couple for primary osteoarthritis. The osteolysis group comprised 317 patients with any osteolysis, with or without aseptic loosening, diagnosed on plain AP and lateral radiographs of the hip using the Harris criteria [16, 17] , and the control group comprised 573 asymptomatic patients at a minimum of 7 years after primary THA and who had not undergone any revision surgery and were free from plain radiographic evidence of osteolysis at the time of recruitment. These participants were identified through hospital records from the north of England and recruited between April 2000 and August 2010 as part of previous ethically approved osteolysis studies [13, 30, 53] and had DNA archived in the South Yorkshire and North Derbyshire Musculoskeletal Biobank.
In both cohorts, patients in the osteolysis group were younger, and a greater proportion were men when compared with the control group (Table 1) . Patients in the control population also had a longer time since primary THA than the patients with osteolysis, and a greater proportion in the Norway cohort had fully cemented prostheses and ceramic-on-polyethylene bearing couples. These findings are consistent with known osteolysis risk factors [15, 18, 49] and were adjusted for by inclusion as covariates in all subsequent analyses.
DNA Sample Quality Control, Genotyping, and Association Analyses
Genomic DNA from the Norwegian cohort was genotyped on the Infinium Illumina HumanCoreExome-24 BeadChip Kit (Illumina, San Diego, CA, USA). Genotypes were called using the Illumina Genome Studio Gencall calling algorithm. All samples underwent standard quality control (QC) procedures with exclusion criteria as follows: (1) call rate < 80%; (2) gender discrepancy; (3) excess heterozygosity (separately for minor allele frequency (MAF) $ 1% and < 1%); (4) duplicates and/or related; (5) ethnicity outliers; and (6) Fluidigm concordance (this identity check looks at sample concordance between Illumina and Fluidigm genotypes). Variants were excluded based on the following: (1) call rate < 98%; (2) Hardy-Weinberg Equilibrium (HWE) p # 1 x 10 -4 ; (3) cluster separation score < 0.4; (4) MAF < 0.01; and (5) less than four minor allele counts in cases and controls separately. In total, after the exclusion of samples and variants that failed the QC criteria, 779 osteolysis patients, 1845 control patients, and 508,957 directly typed SNPs remained. Phasing and imputation were carried out remotely on the Haplotype Reference Consortium (HRC) free servers using IMPUTE2 and SHAPEIT3 software (http://www.haplotypereference-consortium.org/). Briefly, the HRC reference panel consists of 64,976 human haplotypes at 39,235,157 SNPs using whole-genome sequence data from 20 studies of predominantly European ancestry [38] . After imputation and additional QC exclusions (variants with MAF < 0.05, HWE p # 10 -4 , and imputation info score # 0.4), the number of variants reached 5,397,933 and 5,397,567 for case-control status and time-to-revision analyses, respectively. In all, 2624 individuals (779 patients with osteolysis and 1845 patients in the control group) passed the QC criteria and were used in the case-control analysis, and in the time-to-revision analysis, only cases were used.
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Genomic DNA from patients in the UK cohort was genotyped using the Illumina 610k beadchip. After QC, the data set was phased and imputed using the HRC reference panel by applying the same QC metrics used for the Norwegian cohort. After QC, 5,314,896 variants in 890 individuals proceeded to case-control analysis and 5,415,184 variants in 317 individuals proceeded to time-to-revision analysis.
Association analyses for osteolysis case-control status and time to revision in those patients with osteolysis were conducted separately for the Norwegian and UK cohorts and made using the frequentist likelihood ratio test and method ml in SNPTEST v2.5.2 (https://mathgen.stats.ox.ac.uk/ genetics_software/snptest/) [36] . To account for population stratification, the first 10 principal components were included as covariates in the association testing. Sex, age at operation, prosthesis fixation method, bearing couple material combination, and lysis-free survival were also used as covariates in the association analysis. The same covariates were used for the time-to-prosthesis revision analysis. Because of the large number of variants tested in genomic studies and the variable levels of linkage (nonindependence) between the variables, p values of # 5 x 10 -6 were taken as indicating a suggestive association between variant and disease status and p # 5 x 10 -8 as indicating genome-wide significance. Power was calculated using Quanto v1.2.4 [38] using p = 5 x 10 -8 and fixed the sample size to the size of each cohort separately.
Meta-analysis
We performed a meta-analysis of the two analyzed cohorts using the fixed-effects inverse-variance weighted model implemented in METAL (http://www.sph.umich.edu/csg/ abecasis/metal/) [54] . The total sample size in the combined cohort consisted of 1096 patients and 2418 control group participants. Variants with per-cohort MAF 0.05, imputation information score > 0.4, and HWE p $ 10 -4 were included in the analysis. To test the heterogeneity of the results, we computed Cochran's Q and the I 2 statistic.
Data Availability
Anonymized genotypes of the Norwegian cohort included in this study are publicly available through the European Genome-Phenome Archive (EGA) under accession number EGAS00001001883, data set EGAD00010001289.
Results

Genetic Loci Associated With Osteolysis Casecontrol Status
In the Norwegian cohort, we found a total of 12 SNPs comprising four independent signals (Manhattan plot [ Fig. 1A ], QQ plot [ Fig. 1B] ) that were associated with osteolysis casecontrol status at p # 5 x 10 -6
. A summary of the loci associated with osteolysis is shown (see Table, ).
In the UK cohort, we identified a total of 61 SNPs comprising 11 independent signals (Manhattan plot [ Fig. 2A ], . A summary of the loci associated with osteolysis case-control status is shown (see Table, ) and lies between the PLXNA2 (plexin A2) and MIR205HG genes on chromosome 1.
Genetic Loci Associated With Time to Prosthesis Revision
In the Norwegian cohort, we identified 32 SNPs comprising five independent signals (Manhattan plot [ Fig. 3A] , QQ plot [ Fig. 3B ]) that were associated with time to revision at p # 5 x 10 -6 . A summary of the loci associated with time to revision is shown (see Table, Supplemental Digital Content 3). ) and lies between the VEZT (vezatin, adherens junctions transmembrane protein) and METAP2 (methionyl aminopeptidase 2) protein coding genes on chromosome 12.
Genome-wide analysis in the UK cohort identified 19 signals comprising nine independent signals (Manhattan plot [ Fig. 4A ], QQ plot [ Fig. 4B ]) that were associated with time to revision at p # 5 x 10 -6 . A summary of the loci associated with time-to-revision status is shown (see Table, Supplemental Digital Content 4). The variant with the most statistically significant p value was rs184396151 (EA G, EAF 0.67; beta 6 SE 1.34 6 0.17; p = 6.70 x 10 -7
) and lies within CUX2 (cutlike homeobox 2) protein coding gene on chromosome 12.
Genetic Loci Association Meta-analyses
The results showed that 5,411,522 variants with MAF $ 0.05 were common to both the Norwegian and UK osteolysis case-control analyses. After meta-analysis, no signals approached the genome-wide significance threshold of p # 5 x 10 -8 (Manhattan plot [ Fig. 5A ], QQ plot [ Fig. 5B]) . A summary of the loci that were associated with osteolysis case-control status at p # 5 x 10 -6 is shown (see Table, Supplemental Digital Content 5). Twenty-nine SNPs, with the same direction of effect in both cohorts and comprising five independent signals, showed suggestive evidence for an association with osteolysis susceptibility with p # 5 x 10 -6 . The strongest signal was in chromosome 7 ( Fig. 6) (DPY19L2 pseudogene 3) .
In a meta-analysis across the Norwegian and UK cohorts for time to revision, a total of 5,418,572 variants were analyzed (Manhattan plot [ Fig. 7A], QQ plot [Fig. 7B]) . A summary of the loci that were associated with time to revision at p # 5 x 10 -6 is shown (see Table, Supplemental Digital Content 6). In all, 209 variants with the same direction of effect in both cohorts and comprising 11 independent signals showed suggestive evidence for an association with time-toprosthesis revision with p # 5 x 10 -6
. rs10507055 (Fig. 8) had the most statistically significant p value (EA T, EAF 0.37; beta 6 SE -0.22 6 0.04; p = 1.40 x 10 -7
) and is in the same region of chromosome 12 as rs282329, which had the most statistically significant p value in the Norwegian cohort association analysis. A block of 174 correlated variants with p # 5 x 10 -6 was found in chromosome 15 ( Fig. 9) . rs12899987 is the lead variant and lies within the gene OTUD7A (EA T, EAF 0.81; beta 6 SE 0.26 6 0.05; p = 2.80 x 10 -7
).
Discussion
Although osteolysis after THA has been mitigated substantially by the use of highly crosslinked polyethylene bearings, osteolysis and its sequelae aseptic loosening remain a leading indication for revision surgery. Previous studies have observed that interindividual differences in susceptibility to osteolysis may have a genetic basis [1, 2, 34, 53] , but this question has not been examined systematically at the genome-wide level. In this study, in two European cohorts, we explored the contribution that variation across the human genome makes to osteolysis and found evidence of a modest heritable contribution to disease susceptibility. We found replicating evidence for not been characterized previously and its function is unknown. However, this signal also lies adjacent to micro-RNA 550a-3 (MiR550A3). MicroRNAs are a recently discovered group of RNAs that function to regulate the production of other peptides and are currently being explored as putative biomarkers and treatments for musculoskeletal and other diseases [4, 6, 39, 42] . In our quantitative trait meta-analysis of time-to-prosthesis revision, we identified a large block of 174 correlated variants in chromosome 15. The lead signal for this block was intronic variant rs12899987 that lies within the gene encoding OTU deubiquitinase 7A (OTUD7A). OTUD7A is an intracellular enzyme that modulates NFkB signaling through TRAF6 that is pivotal in proinflammatory cytokine signaling in periprosthetic osteolysis [55] and represents a potentially actionable target in its prevention [29] . The most statistically significant signal in the time-to-revision analysis lies within the gene LOC105369917. The function of this gene has not been explored. However, this signal also lies adjacent to two further microRNA sites, MiR331 and MiR3685. Further exploration by fine mapping of these loci is required to identify the causal variants at each signal. This study has several limitations. Although these cohorts represent a nationwide and a large regional cohort purposely collected for the study of osteolysis genetics, the sample sizes remain small compared with other populationbased genomic studies [10, 50, 57] . For the case-control analysis, we had > 80% power to detect ORs of 1.5 to 1.9 for variants with MAF 5% to 15% using the combined sample size and combined case-control ratio (1:2.2). For the continuous trait, we assumed a population mean of 0 and a SD of 1. The combined sample size had > 80% power to detect variants at genome-wide significance (p < 5 x 10 -8 ) with a modest effect size (beta of 1.3 to 1.5) for common variants (MAF, 0.5 to 0.15) and a moderate effect size (beta of 1.6 to 2.0) for variants with MAF 0.14 to 0.05. However, similar sample sizes have been used previously to identify the genetic underpinnings in other complex musculoskeletal diseases, including the association of Wnt signaling with Dupuytren's disease (n = 960 cases) [8] .
The case-ascertainment approach also differed between the cohorts. The UK participants were recruited face to face using the primary hospital record and included radiographic evidence of osteolysis or the revision operative record, as described previously, and comprised all patients who fit the relevant inclusion and exclusion criteria. The known epidemiologic risk factors for osteolysis were therefore also reflected in the UK study population. Although this provides evidence for the generalizability of our findings to other populations, we had to adjust for these covariates in the genetic association analyses. All analyses are shown postadjustment for these clinical risk factors as well as for an unidentified population and analytical stratification using principal component and regression analysis. The Norwegian cohort study design and recruitment used the Norwegian Arthroplasty Register as the source data set with documented revision events and indications recorded by the operating surgeon. The patients with osteolysis were recruited before the control patients and at a control:case ratio of 3:1 with screening to match the demographic characteristics and implant type and operation year (6 2 years) as closely as possible. This approach allowed the recruitment of a large case-control matched population but increases the risk of ascertainment bias because patients with silent osteolysis may have been recorded as controls and cases could have been misdiagnosed. Despite this approach, small statistical differences in population demographics remained because of the large sample sizes involved, although their clinical relevance may be limited. For example, the mean age at primary operation in the Norwegian control patients was 66 years, whereas it was 64 years in the patients with osteolysis. We adjusted for these residual differences in the Norwegian cohort association analysis in the same manner as we did for the UK cohort. We found more genetic signals within the UK versus the Norwegian population despite the smaller cohort size. These differences may be genuine. The observed differences might also reflect differences in case ascertainment or other unknown biases between the cohorts. However, the populationlevel genomic architecture of both cohorts by variant allele frequency was similar, indicating no significant genetic heterogeneity between the cohorts. The study participants in each cohort also came from different healthcare economies with potential differences in diagnostic and treatment thresholds. Individual surgeons' clinical practices also differ, resulting in management variation both between and within the cohorts. However, these types of classification differences are unlikely to map to particular genotypes, and thus their likely effect is to create noise limiting the ability of the study to detect genuine genetic signals rather than increasing the false-positive discovery rate.
We, and others, have previously shown the association of osteolysis with variation in several candidate genes [11, 30] . In these studies, the genes are selected based on their known biologic function or a previous association of the selected variants with other diseases that share biologic similarities. The threshold for statistical significance is also set low (typically at p < 0.05), favoring the identification of a positive association. Although these discovery studies lend support to the concept of a disease driven by heritable variation, these associations commonly are not reproduced when examined in independent cohorts [46] , and the overall contribution of genetic variation to the disease remains unanswered. In contrast, genome-wide studies allow examination of the overall genetic architecture of the disease that underpins the differences in susceptibility between individuals. However, these studies require larger sample sizes and are accompanied by substantially more stringent thresholds for significance. The data presented here suggest the association of several previously unstudied genomic loci with osteolysis.
The observations that such loci may reside within areas of the genome about which we still know very little provide the opportunity for novel avenues for exploration of the disease. However, further replication of the observed associations is required to confirm their validity, finemapping to precisely localize causal associations, and experimental study of their biologic function will enable us to clearly understand their role in osteolysis biology and to translate this new knowledge into diagnostic and therapeutic tools.
